A new trading day began on Tuesday, with 4D Molecular Therapeutics Inc (NASDAQ: FDMT) stock price up 4.80% from the previous day of trading, before settling in for the closing price of $7.5. FDMT’s price has ranged from $2.23 to $12.34 over the past 52 weeks.
During the last 5-year period, the sales drop of Healthcare Sector giant was -9.89%. Meanwhile, its annual earnings per share averaged -9.35%. With a float of $52.01 million, this company’s outstanding shares have now reached $57.14 million.
4D Molecular Therapeutics Inc (FDMT) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of 4D Molecular Therapeutics Inc is 8.97%, while institutional ownership is 65.20%. The most recent insider transaction that took place on Dec 20 ’25, was worth 3,377. In this transaction VP, Finance and Controller of this company sold 389 shares at a rate of $8.68, taking the stock ownership to the 46,218 shares. Before that another transaction happened on Dec 16 ’25, when Company’s Chief Legal Officer sold 1,635 for $10.90, making the entire transaction worth $17,822. This insider now owns 3,594 shares in total.
4D Molecular Therapeutics Inc (FDMT) Earnings and Forecasts
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.9 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.93 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.35% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.65% during the next five years compared to -9.89% drop over the previous five years of trading.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
Here are 4D Molecular Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.42. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3742.32.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.94, a number that is poised to hit -0.53 in the next quarter and is forecasted to reach -3.48 in one year’s time.
